Yu W, Zhou D, Meng F, Wang J, Wang B, Qiang J
BMC Cancer. 2025; 25(1):186.
PMID: 39891086
PMC: 11786447.
DOI: 10.1186/s12885-025-13471-y.
Lin L, Huang Y, Qian S, Chen L, Sun H
Front Nutr. 2025; 11:1466509.
PMID: 39882037
PMC: 11774697.
DOI: 10.3389/fnut.2024.1466509.
Zhu Y, Qi Z, Zu S, Yang F, Wang Y, Zhu L
BMC Cancer. 2025; 25(1):165.
PMID: 39875873
PMC: 11776251.
DOI: 10.1186/s12885-025-13567-5.
Koizumi F, Katoh N, Kanehira T, Kawamoto Y, Nakamura T, Kakisaka T
Phys Imaging Radiat Oncol. 2025; 33():100690.
PMID: 39817285
PMC: 11733268.
DOI: 10.1016/j.phro.2024.100690.
Chen J, Wang D, Xiong F, Wu G, Liu W, Wang Q
J Gastrointest Oncol. 2025; 15(6):2692-2705.
PMID: 39816022
PMC: 11732357.
DOI: 10.21037/jgo-24-549.
Elevated Expression of Cell Adhesion, Metabolic, and Mucus Secretion Gene Clusters Associated with Tumorigenesis, Metastasis, and Poor Survival in Pancreatic Ductal Adenocarcinoma.
Balakrishnan K, Xiao Y, Chen Y, Dong J
Cancers (Basel). 2024; 16(23).
PMID: 39682235
PMC: 11640259.
DOI: 10.3390/cancers16234049.
Radioresistance-related gene signatures identified by transcriptomics characterize the prognosis and immune landscape of pancreatic cancer patients.
Wang D, Cao J, Chen Y, Zhang L, Zhou C, Huang L
BMC Cancer. 2024; 24(1):1497.
PMID: 39639217
PMC: 11619475.
DOI: 10.1186/s12885-024-13231-4.
Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC.
Yao Z, Zhang H, Huang K, Huang G, Xi P, Jiang L
Transl Oncol. 2024; 51:102206.
PMID: 39603206
PMC: 11635771.
DOI: 10.1016/j.tranon.2024.102206.
An Atypical Case of Pancreatic Cancer with Mesenchymal Differentiation in a Patient with Primary Lung Adenocarcinoma: Insights into Tumor Biology and Novel Therapeutic Pathways.
Abbas N, Zahreddine L, Tawil A, Natout M, Shamseddine A
Diagnostics (Basel). 2024; 14(22).
PMID: 39594178
PMC: 11592984.
DOI: 10.3390/diagnostics14222512.
Recent efficacy and long-term survival of polysaccharide combined with gemcitabine and S-1 in pancreatic cancer.
Li G, Jiang J
World J Clin Oncol. 2024; 15(11):1404-1411.
PMID: 39582615
PMC: 11514418.
DOI: 10.5306/wjco.v15.i11.1404.
Identification of M2 macrophage-related genes for establishing a prognostic model in pancreatic cancer: as key gene.
Wang Z, Fu J, Zhu S, Tang H, Shi K, Yang J
Oncol Res. 2024; 32(12):1851-1866.
PMID: 39574475
PMC: 11576954.
DOI: 10.32604/or.2024.055286.
A collagenase-decorated Cu-based nanotheranostics: remodeling extracellular matrix for optimizing cuproptosis and MRI in pancreatic ductal adenocarcinoma.
Wang Y, Zhou Q, Luo W, Yang X, Zhang J, Lou Y
J Nanobiotechnology. 2024; 22(1):689.
PMID: 39523309
PMC: 11552245.
DOI: 10.1186/s12951-024-02968-6.
GL-V9 Promotes Autophagy-Mediated YAP1 Degradation and Activates Mitochondrial Apoptosis in PDAC Cells.
Liu H, Lin Z, Guo Y, Zhou Y, Li W
Pharmaceuticals (Basel). 2024; 17(10).
PMID: 39458993
PMC: 11510253.
DOI: 10.3390/ph17101352.
Targeting the CSF1/CSF1R signaling pathway: an innovative strategy for ultrasound combined with macrophage exhaustion in pancreatic cancer therapy.
Wang Q, Wang J, Xu K, Luo Z
Front Immunol. 2024; 15:1481247.
PMID: 39416792
PMC: 11479911.
DOI: 10.3389/fimmu.2024.1481247.
Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?.
Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C
Cells. 2024; 13(18.
PMID: 39329742
PMC: 11430323.
DOI: 10.3390/cells13181558.
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective.
Shao H, Fang H, Li Y, Jiang Y, Zhao M, Tang W
Cost Eff Resour Alloc. 2024; 22(1):70.
PMID: 39294689
PMC: 11412000.
DOI: 10.1186/s12962-024-00578-5.
Establishment of a prognostic model for pancreatic cancer based on mitochondrial metabolism related genes.
Ba Q, Wang X, Lu Y
Discov Oncol. 2024; 15(1):376.
PMID: 39196457
PMC: 11358576.
DOI: 10.1007/s12672-024-01255-y.
Radiogenomic analysis for predicting lymph node metastasis and molecular annotation of radiomic features in pancreatic cancer.
Tang Y, Su Y, Zheng J, Zhuo M, Qian Q, Shen Q
J Transl Med. 2024; 22(1):690.
PMID: 39075486
PMC: 11288107.
DOI: 10.1186/s12967-024-05479-y.
Identified γ-glutamyl cyclotransferase (GGCT) as a novel regulator in the progression and immunotherapy of pancreatic ductal adenocarcinoma through multi-omics analysis and experiments.
Zheng Y, Xiong Q, Yang Y, Ma Y, Zhu Q
J Cancer Res Clin Oncol. 2024; 150(6):318.
PMID: 38914714
PMC: 11196309.
DOI: 10.1007/s00432-024-05789-0.
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.
Zheng R, Liu X, Zhang Y, Liu Y, Wang Y, Guo S
Front Immunol. 2024; 15:1383978.
PMID: 38756774
PMC: 11096556.
DOI: 10.3389/fimmu.2024.1383978.